Author (tumour type) | year | ref. | years MP use | total tumours cases/controls and OR (95%CI) | ipsilateral tumours cases/controls and OR (95%CI) | contralateral tumours cases/controls and OR (95%CI) | |||
---|---|---|---|---|---|---|---|---|---|
Lonn et al. | 2004 | 40 | since ≥ 10 | 14/29 | 1.9 (0.9-4.1) | 12/15 | 3.9 (1.6-9.5) | 4/17 | 0.8 (0.2-2.9) |
(acoustic neuromas) |  |  | for ≥ 10 | 11/26 | 1.6 (0.7-3.6) | 9/12 | 3.1 (1.2-8.4) | 4/16 | 0.8 (0.2-3.1) |
Schoemaker et al. 2005 |  | 43 | since ≥ 10 | 47/212 | 1.0 (0.7-1.5) | 31/124 | 1.3 (0.8-2.0) | 20/105 | 1.0 (0.6-1.7) |
(acoustic neuromas) |  |  | for ≥ 10 | 31/131 | 1.1 (0.7-1.8) | 23/72 | 1.8 (1.1-3.1) | 12/73 | 0.9 (0.5-1.8) |
Lonn et al. | 2005 | 41 | since ≥ 10 | 25/38 | 0.9 (0.5-1.5) | 15/18 | 1.6 (0.8-3.4) | 11/25 | 0.7 (0.3-1.5) |
(gliomas) |  |  | for ≥ 10 | 22/33 | 0.9 (0.5-1.6) | 14/15 | 1.8 (0.8-3.9) | 9/23 | 0.6 (0.3-1.4) |
(meningiomas) |  |  | since ≥ 10 | 12/36 | 0.9 (0.4-1.9) | 5/18 | 1.3 (0.5-3.9) | 3/22 | 0.5 (0.1-1.7) |
 |  |  | for ≥ 10 | 8/32 | 0.7 (0.3-1.6) | 4/15 | 1.4 (0.4-4.4) | 3/23 | 0.5 (0.1-1.8) |
Hepworth et al. | 2006 | 46 | since ≥ 10 | 66/112 | 0.9 (0.6-1.3) |  |  |  |  |
(gliomas) |  |  | for ≥ 10 | 48/67 | 1.14 (0.74-1.73) |  |  |  |  |
 |  |  | regular use |  |  | 278/486 | 1.24 (1.02-1.52) | 199/491 | 0.75 (0.61-0.93) |
Schuz et al. | 2006 | 47 | females only ≥ 0.5 | 30/38 | 1.96 (1.1-3.5) |  |  |  |  |
(gliomas) | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Lonn et al. | 2006 | 48 | since ≥ 10 | 7/15 | 1.4 (0.5-3.9) | 6/9 | 2.6 (0.9-7.9) | 1/9 | 0.3 (0.0-2.3) |
(parotid gland tumours) |  |  | for ≥ 10 | 5/13 | 1.1 (0.4-3.6) | 4/8 | 2.0 (0.5-7.0) | 1/8 | 0.3 (0.0-2.6) |
Klaeboe et al. | 2007 | 49 | since ≥ 6 | 70/73 | 0.8 (0.5-1.2) | 39/37 | 1.3 (0.8-2.1) | 32/42 | 0.8 (0.5-1.4) |
(gliomas) |  |  | for ≥ 6 | 55/61 | 0.7 (0.4-1.2) | 30/30 | 1.2 (0.7-2.1) | 27/34 | 0.9 (0.5-1.5) |
Lahkola et al. | 2007 | 50 | since ≥ 10 | 143/220 | 0.95 (0.74-1.23) | 77/117 | 1.39 (1.01-1.92) | 67/121 | 0.98 (0.71-1.37) |
(gliomas) |  |  | for ≥ 10 | 88/134 | 0.94 (0.69-1.78) | 43/74 | 1.14 (0.76-1.72) | 41/71 | 1.01 (0.67-1.53) |
Lahkola et al. | 2008 | 54 | since ≥ 10 | 73/212 | 0.91 (0.67-1.25) | 33/113 | 1.05 (0.67-1.65) | 24/117 | 0.62 (0.38-1.03) |
(meningiomas) |  |  | for ≥ 10 | 42/130 | 0.85 (0.57-1.26) | 21/73 | 0.99 (0.57-1.73) | 13/68 | 0.64 (0.33-1.23) |
Interphone | 2010 | 72 | ≥ 1640 calls | 160/113 | 1.82 (1.15-2.89) | 100/62 | 1.96 (1.22-3.16) | 39/31 | 1.25 (0.64-2.42) |
(gliomas) | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Sadetzki et al. | 2008 | 53 | > 5479 calls | 86/157 | 1.13 (0.79-1.61) | 121/159 | 1.58 (1.11-2.24) | 46/135 | 0.78 (0.51-1.19) |
(parotid gland tumours) | Â | Â | > 266.3 hours | 80/155 | 1.03 (0.72-1.47) | 115/158 | 1.49 (1.05-2.13) | 48/129 | 0.84 (0.55-1.28) |
 |  |  | > 5479 calls <5-year latency | 47/82 | 1.16 (0.74-1.82) | 35/40 | 1.80 (1.05-3.10) | 12/41 | 0.63 (0.31-1.30) |
" | Â | > 5479 calls >5-year latency | 120/215 | 1.08 (0.77-1.50) | 86/119 | 1.50 (1.03-2.20) | 34/94 | 0.84 (0.52-1.34) | |
only regular users | > 5479 calls | 86/157 | 1.48 (1.05-2.10) | Â | Â | Â | Â | ||
" | > 18997 calls | 81/140 | 1.51 (1.05-2.17) | Â | Â | Â | Â | ||
" | > 1035 cumulative calls | 83/134 | 1.50 (1.04-2.16) | Â | Â | Â | Â | ||
 |  |  | ≥ 18997 calls, urban areas | 49/99 | 1.00 (0.65-1.55) |  |  |  |  |
 |  |  | " rural areas | 32/41 | 1.81 (1.04-3.14) |  |  |  |  |
 |  |  | ≥ 1035 hours, urban areas | 51/96 | 1.02 (0.67-1.58) |  |  |  |  |
 |  |  | " rural areas | 32/38 | 1.96 (1.11-3.44) |  |  |  |  |